Empower Pharmacy | Securing Media Coverage Favorable to Compounding Pharmacies
Empower Pharmacy faced a significant challenge when a major pharmaceutical company was granted an NDA (new drug application) for Ascor® (Ascorbic Acid Injection Solution), with the approved indication being scurvy (vitamin C deficiency). The drug was also granted Orphan Drug status. This designation access severely restricted the ability of compounding pharmacies, like Empower Pharmacy, to deliver ascorbic acid injection solutions as an adjunct therapy in the treatment of many other conditions, such as chronic renal failure, severe burns, hypertension, COVID-19 and wound healing.
Pierpont identified two primary objectives for Empower Pharmacy:
- Raise awareness about the impact of the Orphan Drug status on compounding pharmacies' ability to provide essential treatments.
- Position Empower Pharmacy and its CEO, Shaun Noorian, as advocates for affordable and accessible compounded medications, while highlighting Noorian's personal story and commitment to disrupting the pharmaceutical industry.
Success would be measured by securing media coverage that reached targeted outlets and conveyed Empower Pharmacy’s message to a broad audience.
Pierpont’s efforts resulted in widespread media coverage for Empower Pharmacy, with placements in prominent outlets including Houston Business Journal, Bisnow, Houston Chronicle, Innovation Map, Area Development, and Community Impact, among others. The grand opening event was a success, showcasing Empower’s new facility and enhancing the company’s visibility within the pharmaceutical industry.
